Page 1596 - Small Animal Internal Medicine, 6th Edition

1568 Index

Neuroophthalmologic evaluation Nonthyroidal Illness Syndrome (NTIS), Oral cavity disorders (Continued) Oxygen supplementation
(Continued) 779–780, 780f salivary gland necrosis, 447 administration of, 383, 383t, 384f
lacrimal gland function, 1086 NT-proBNP, 13–14, 162–163 sialoadenitis, 447 endotracheal tubes for, 384
VetBooks.ir pupil size and symmetry, 1086 Nuclear hypersegmentation, 1372 sialocele, 447 heart failure treated with, 61
flow rates, 383t
Nuclear cardiology, 18
menace response, 1084, 1085f, 1085b
sialoadenosis, 447
Nuclear imaging, 296
pupillary light reflex, 1084–1085,
stomatitis, 450, 450b
indications for, 383
1085f, 1086t
vision, 1084 Nucleus of Onuf, 730 Oral cavity neoplasms pulmonary parenchymal disorders
treated with, 381
in cats, 449
Nutrition. see also Diet
Neuroparalytic keratitis, 1160–1161 for acute pancreatitis, 631–632, 631b, in dogs, 447–449, 448t tracheal tubes for, 384–385
Neutropenia, 1372–1375 632f Oral dexamethasone suppression test, Oxyhemoglobin dissociation curve, 315,
afebrile, 1279–1280, 1375 Nutritional supplementation, 435–437 866t, 870 316f
causes of, 1244t, 1373b Nutritional therapy Oral hypoglycemic drugs, 835–837 Oxymetazoline, 386t–388t
chemotherapy-related, 1278, 1279f nasoesophageal tube feeding, 435 Oral rehydration therapy, 433–434 Oxymorphone, 227b, 1134t
comorbid conditions with, 1373 orogastric tube feeding, 435 Orbax. see Orbifloxacin Oxytocin, 969–972, 1034t–1036t
corticosteroid-responsive, 1375, 1375f Nyquist limit, 28 Orbifloxacin, 386t–388t, 515t–517t, P
definition of, 1372–1373 Nystagmus, 1055–1057, 1058f, 1109 1437t–1438t
evaluation of, 1374, 1374f O Orchitis, 1003–1004 Packed cell volume, 1420
febrile, 1279–1280 Organophosphates, 1099b Packed red blood cell transfusion, 1237
fever associated with, 1426t Obesity, 899–907 Ormetoprim-sulfadimethoxine, Pain
immune-mediated, 1244–1245 adverse effects of, 899b 1437t–1438t abdominal, 408, 410b, 519
parvoviral enteritis with, 1373–1374 body condition scoring for, 901, Orogastric tube feeding, 435 assessment of, 1052f–1054f,
pathogenesis of, 1375 902f–903f Oropharyngeal disorders 1053–1054
signs of, 1373–1374 body weight measurements, 901 salivary gland necrosis, 447 deep, 1052f
Neutrophil(s) definition of, 899 sialoadenitis, 447 joint, 1203f
description of, 1192 diagnosis of, 901 sialoadenosis, 447 neck, 1053, 1053f–1054f, 1055b,
giant, 1372 dietary considerations for, 73 sialocele, 447 1117–1119, 1118b
morphologic abnormalities of, dog breeds commonly affected, 900b Orthopnea, 379 polyarthritis, 1187
1371–1372 drug and, 901 Oslerus osleri, 296, 297t, 337–338, spinal, 1053f–1054f, 1134t
physiology of, 1372, 1372f endocrine abnormalities associated 338f Palpebral reflex, 1056t
pools of, 1372f with, 901 Osmolality, urine, 662–663 PAM. see Pralidoxime chloride
stimulation of production, 1375 etiology of, 899–901, 900b Osmotic diuretics, 691 Pamidronate, 927, 934t, 1327b
toxic, 1371–1372, 1372f nutritional considerations, 903, Osmotic laxatives, 445 Panacur. see Fenbendazole
Neutrophil gelatinase-associated 904t–906t Ossifying epulis, 448t Pancreas
lipocalin (NGAL), 660 prevention of, 907 Osteoarthritis. see Degenerative joint anatomy of, 620, 622t
Neutrophilia, 134, 1375–1376, 1376b, treatment of, 901–907, 904t–906t disease biopsies, 558–559
1426t Obstetrics. see Pregnancy Osteolysis, 1146 exocrine. see Exocrine pancreatic
Neutrophilic cholangitis, 568t, 569–570, Obstructive laryngitis, 280 Osteomyelitis, 1440t, 1443 insufficiency
569f Obturator nerve, 1158t Osteopetrosis, 1355b, 1386 function of, 622t
New methylene blue stain, 1258 Occult blood, in urine, 665 Osteosarcoma normal canine, 621f
New York Heart Association heart failure Occult hyperadrenocorticism, 878 appendicular, 1325–1326 structure, 622t
classification scheme, 59–60 Octreotide, 441. see also Somatostatin chemotherapy for, 1327b Pancreatic disease, 518–530
Nexium. see Esomeprazole Ocular lymphoma, 1296, 1309 clinical features of, 1325–1326 diagnostic approach to, 532
Niacin, 913 Oculocephalic reflex, 1109 diagnosis of, 1326 drugs used in, 643t–648t
Nifurtimox, 1526 Oculomotor nerve, 1055, 1056t epidemiology of, 1325 gastrointestinal signs with, 518–519,
Nitazoxanide, 1443 Olfactory nerve, 1056t etiology of, 1325 519b
Nitrates, 71–72 Oliguria, 688f metastasis of, 1290t Pancreatic endocrine function, tests of,
Nitric oxide, 58, 221 Ollulanus tricuspis, 463, 465 prognosis for, 1327–1328 540
Nitroglycerin, 63 Olsalazine, 441, 515t–517t radiographic findings, 1326, 1326f Pancreatic enzymes, 515t–517t
Nitroimidazoles, 1437t–1439t Omega-3 fatty acids, 72–73 round cells associated with, 1260–1261 assays of, 625–626
Nitroprusside, 217t Omeprazole, 439t, 515t–517t treatment of, 1327–1328 in exocrine pancreatic insufficiency,
Nizatidine, 439–441 immune-mediated diseases treated Osteosclerosis, 1355b, 1386 639
Nizoral. see Ketoconazole with, 1255t–1256t Otitis media-interna Pancreatic exocrine function, tests of,
Nocardia spp., 1429–1430 Omnizole. see Thiabendazole facial nerve paralysis caused by, 540
Nocturia, 649 Omphalitis, 1020 1161f Pancreatic inflammation, specific tests of,
Nodular hyperplasia, 613 Oncogenes, 1269 imaging of, 1112–1113 538–540, 539t
Nonabsorbable aminoglycosides, 442 Oncologic disorders peripheral vestibular disease caused Pancreatic lipase immunoreactivity
Nonbronchoscopic bronchoalveolar cancer. see Cancer by, 1112–1113, 1112f (PLI), 538–539, 625–626
lavage, 305–310 leukemia. see Leukemias treatment of, 1113, 1161, 1440t Pancreatic secretory trypsin inhibitor,
in cats, 307, 307f lymphoma. see Lymphoma Ovarian cysts, 955–956, 955f–956f 621
complications of, 305–307, 306f Ondansetron, 438, 515t–517t Ovarian neoplasias, 954 Pancreatic system
in dogs, 307–308, 308f o,p’DDD, 896t–897t Ovarian remnant syndrome, 982–983, diagnostic approach for, 531–545
indications for, 305–307, 306f Open-mouth breathing, 4, 4f 983f diagnostic tests for, 531–560
Noncirrhotic portal hypertension, 609f, Ophthalmologic disorders, 1031 Ovariohysterectomy, 973–974, 1446 Pancreatitis, 620–636
610–611 Opisthotonos, 1181 Overactive bladder, 736–737 acute
Nonerosive immune-mediated Optic chiasm lesions, 1088 Overflow incontinence, 735–736 analgesia for, 628–631, 629t–630t
polyarthritis, 1187, 1188f, caudal, 1088–1089, 1089f Overhydration, 358, 433 antibiotics for, 633
1202–1204, 1202b Optic disk lesions, 1087–1088 Ovulation antiemetics for, 632–633
Noninfectious inflammatory disease, Optic nerve in bitch biliary tract obstruction and, 633
1143 description of, 1055, 1056t estrogen levels, 940–942 in cats, 624f
Noninfective myocarditis, 154–155 lesions of, 1087–1088 luteinizing hormone levels, 942 chronic pancreatitis versus, 623t
Nonischemic priapism, 996 Optic neuritis, 1087–1088, 1088b progesterone levels, 942–943 clinical features of, 621–625, 623t,
Nonproductive cough, 282 Optic radiation, 1084 timing of, 940–945 624f
Non-protein-losing malabsorptive Oral cavity ultrasonography detection of, 943, description of, 620
disease, 399–401, 491–492 imaging of, 416–419 943f–944f diagnosis of, 625–627
Nonregenerative anemia, 1218t–1219t, squamous cell carcinoma of, 448t induction diagnostic imaging of, 626–627,
1351–1355, 1352b, 1358f, 1426t Oral cavity disorders during estrus, 1034t–1036t 627f
Nonseptic exudates, 362f, 363 atrophic myositis, 451 in queens, 949 etiology of, 621, 623t
Nonspecific reactive hepatitis, 617 cricopharyngeal achalasia/dysfunction, Ovuplant. see Deslorelin fluid analysis for, 627
Nonsteroidal anti-inflammatory drugs, 451–452 Oxacillin, 1437t–1438t gastroprotectants for, 633
629t–630t feline eosinophilic granuloma, Oxybutynin, 733t–734t histopathology of, 627
acute kidney injury caused by, 449–450 Oxygen cages, 379, 383t, 385 intravenous fluids and electrolytes
686–687 feline lymphocytic-plasmacytic Oxygen hoods, 383, 384f for, 628
degenerative joint disease treated with, gingivitis, 450–451 Oxygen masks, 383 necrotizing, 628
1197t gingivitis, 450 Oxygen saturation nutrition for, 631–632, 631b, 632f
gastrointestinal ulceration/erosion masticatory muscle myositis, 451 of hemoglobin, 318 pancreatic enzyme assays, 625–626
treated with, 470–471 periodontitis, 450 pulse oximetry evaluation of, 65 pathogenesis of, 621, 623t